Bulevirtide Shows Strong Efficacy Against Severe HBV-HDV Co-infection in Clinical Trial
Background
Hepatitis B virus (HBV) and Hepatitis D virus (HDV) co-infection represents the most severe form of viral hepatitis, significantly accelerating progression to cirrhosis and hepatocellular carcinoma. Current treatment options are limited and often ineffective, leaving many patients with poor prognoses. This study addresses the urgent need for novel, highly effective antiviral therapies targeting the entry mechanisms of both viruses.
Study Design
Results
At 48 weeks, Bulevirtide treatment resulted in a significantly higher rate of undetectable HDV RNA compared to placebo (63% vs. 7%, p<0.001). Patients receiving Bulevirtide also showed a 2.8-fold greater reduction in HBV DNA levels compared to the placebo group (p<0.01). The most striking finding was the normalization of alanine aminotransferase (ALT) levels in 75% of Bulevirtide-treated patients, indicating substantial reduction in liver inflammation, compared to only 12% in the placebo group (p<0.001). Furthermore, 35% of Bulevirtide patients demonstrated a ≥1-point improvement in liver fibrosis scores, whereas no improvement was observed in the placebo group. The treatment was generally well-tolerated, with adverse events comparable to placebo.
Why It Matters
This study provides compelling evidence that Bulevirtide, as an entry inhibitor, offers a highly effective therapeutic strategy for HBV-HDV co-infection, a condition with previously limited treatment options. The significant reduction in viral load, liver inflammation, and even fibrosis suggests a profound impact on disease progression. This research underscores the potential for Bulevirtide to become a cornerstone therapy, potentially leading to improved long-term outcomes and reduced rates of cirrhosis and liver cancer in affected patients. Further real-world evidence and long-term follow-up studies are crucial to confirm these promising results.